CL2020001123A1 - Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. - Google Patents

Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.

Info

Publication number
CL2020001123A1
CL2020001123A1 CL2020001123A CL2020001123A CL2020001123A1 CL 2020001123 A1 CL2020001123 A1 CL 2020001123A1 CL 2020001123 A CL2020001123 A CL 2020001123A CL 2020001123 A CL2020001123 A CL 2020001123A CL 2020001123 A1 CL2020001123 A1 CL 2020001123A1
Authority
CL
Chile
Prior art keywords
antibodies
syndrome
treatment
sjögren
therapies
Prior art date
Application number
CL2020001123A
Other languages
English (en)
Inventor
Pascal Espie
Peter Gergely
James Rush
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020001123A1 publication Critical patent/CL2020001123A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA DIVULGACIÓN SE REFIERE A MÉTODOS, REGÍMENES DE TRATAMIENTO, USOS, EQUIPOS Y TERAPIAS PARA TRATAR EL SÍNDROME DE SJÖGREN, MEDIANTE EL EMPLEO DE ANTICUERPOS ANTI–CD40.
CL2020001123A 2017-11-03 2020-04-28 Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren. CL2020001123A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581212P 2017-11-03 2017-11-03
US201862644939P 2018-03-19 2018-03-19

Publications (1)

Publication Number Publication Date
CL2020001123A1 true CL2020001123A1 (es) 2020-10-30

Family

ID=64572395

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020001123A CL2020001123A1 (es) 2017-11-03 2020-04-28 Anticuerpos anti-cd40 para el uso en el tratamiento del síndrome de sjögren.

Country Status (13)

Country Link
US (2) US12065499B2 (es)
EP (1) EP3704158A1 (es)
JP (2) JP2021501748A (es)
KR (1) KR20200074993A (es)
CN (1) CN111263771A (es)
AU (2) AU2018361743A1 (es)
BR (1) BR112020008379A2 (es)
CA (1) CA3076872A1 (es)
CL (1) CL2020001123A1 (es)
IL (1) IL273848A (es)
MX (1) MX2020004411A (es)
TW (1) TW201922783A (es)
WO (1) WO2019087094A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018361743A1 (en) 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
CN116234909A (zh) * 2020-08-21 2023-06-06 上海药明生物技术有限公司 Cd40激动剂抗体和使用方法
US20230331860A1 (en) * 2020-08-25 2023-10-19 Bristol-Myers Squibb Company Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies
WO2023056297A1 (en) * 2021-09-28 2023-04-06 Viela Bio, Inc. Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome
CN121219322A (zh) * 2023-04-03 2025-12-26 赛尔生物股份有限公司 包含重组抗信号素4d阻断抗体作为有效成分的用于预防或治疗干燥综合征的药物组合物
WO2025210517A1 (en) * 2024-04-02 2025-10-09 Kiniksa Pharmaceuticals, Gmbh Humanized anti-cd40 antibodies for treating sjögren's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
KR101223373B1 (ko) 2003-12-25 2013-01-16 교와 핫꼬 기린 가부시키가이샤 항 ｃｄ４０ 항체의 변이체
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
NZ602020A (en) 2010-03-31 2014-05-30 Boehringer Ingelheim Int Anti-cd40 antibodies
JP2013543384A (ja) * 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
BR112018006360A2 (pt) * 2015-09-30 2018-10-09 Janssen Biotech Inc anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
AU2018361743A1 (en) 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome

Also Published As

Publication number Publication date
RU2020117365A (ru) 2021-12-03
BR112020008379A2 (pt) 2020-11-03
AU2018361743A1 (en) 2020-04-09
AU2022201425A1 (en) 2022-03-24
MX2020004411A (es) 2020-08-06
JP7357120B2 (ja) 2023-10-05
CA3076872A1 (en) 2019-05-09
JP2022137233A (ja) 2022-09-21
US20250206833A1 (en) 2025-06-26
US12065499B2 (en) 2024-08-20
WO2019087094A1 (en) 2019-05-09
TW201922783A (zh) 2019-06-16
KR20200074993A (ko) 2020-06-25
EP3704158A1 (en) 2020-09-09
US20190153111A1 (en) 2019-05-23
JP2021501748A (ja) 2021-01-21
RU2020117365A3 (es) 2021-12-24
IL273848A (en) 2020-05-31
CN111263771A (zh) 2020-06-09

Similar Documents

Publication Publication Date Title
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
MX2022015631A (es) Anticuerpos anti-cd40 humanizados y usos de los mismos.
MX2017011834A (es) Macrociclos peptidomimeticos y usos de los mismos.
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
PH12017500825A1 (en) Anti-cldn chimeric antigen receptors and methods of use
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
BR112017006664A2 (pt) terapias de combinação
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
JO3553B1 (ar) تعديل المناعة ضد الورم
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CL2021001829A1 (es) Anticuerpos anti–cd40 para el uso en el tratamiento de hidradenitis supurativa
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX2016010729A (es) Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
MX2017006464A (es) Combinaciones de inhibidor de tlr e inhibidor de tirosina cinasa de bruton.
CL2021002889A1 (es) Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
MX383323B (es) Grelina para uso en el tratamiento de lesión del cerebro traumática leve.
MX2017000306A (es) Metodos para tratar hipotension.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX375318B (es) Formas de dosificación y usos terapéuticos de l-4-cloro quinurenina..